FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to a method for reducing glioblastoma cell proliferation. Said method involves delivery into glioblastoma cells of small interfering RNAs represented by sequences SEQ ID NO: 1 and SEQ ID NO: 2, in combination with chemotherapy with temozolomide TMZ.
EFFECT: invention provides suppression of glioblastoma cell proliferation, which is achieved by overcoming resistance to the classical chemotherapeutic agent temozolomide.
3 cl, 6 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
| PREPARATIONS PROVIDING RNA-INTERFERENCE FOR GST-PI GENE MODULATION | 2015 |
|
RU2719185C2 |
| LINES OF ENGINEERED PRODUCER CELLS AND METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2823068C2 |
| MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
| NUCLEIC ACID CONTAINING REGULATORY ELEMENTS H4C2, AES AND MTRNR1 | 2023 |
|
RU2831168C1 |
| T7 PHAGE DNA-DEPENDENT RNA-POLYMERASE ENZYME PRODUCER STRAIN | 2022 |
|
RU2825469C2 |
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
